Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolNASDAQ:GNOM
CUSIPN/A
Phone+1-650-9432800
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
EmployeesN/A
Outstanding SharesN/A
Market Cap$108.29
Complete Genomics (NASDAQ:GNOM) Frequently Asked Questions
What is Complete Genomics' stock symbol?
Complete Genomics trades on the NASDAQ under the ticker symbol "GNOM."
What is the consensus analysts' recommendation for Complete Genomics?
0 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Complete Genomics in the last year. There are currently for the stock, resulting in a consensus recommendation of "N/A."
Has Complete Genomics been receiving favorable news coverage?
News stories about GNOM stock have trended somewhat negative on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Complete Genomics earned a news impact score of -0.02 on Accern's scale. They also assigned news headlines about the company an impact score of 47.17 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
How do I buy shares of Complete Genomics?
Shares of GNOM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Complete Genomics' stock price today?
One share of GNOM stock can currently be purchased for approximately $3.14.
How big of a company is Complete Genomics?
Complete Genomics has a market capitalization of $108.29 million.
How can I contact Complete Genomics?
Complete Genomics' mailing address is 2071 Stierlin Ct, MOUNTAIN VIEW, CA 94043-4655, United States. The company can be reached via phone at +1-650-9432800.
MarketBeat Community Rating for Complete Genomics (NASDAQ GNOM)
MarketBeat's community ratings are surveys of what our community members think about Complete Genomics and other stocks. Vote "Outperform" if you believe GNOM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNOM will underperform the S&P 500 over the long term. You may vote once every thirty days.
